Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: The NICE 3 story

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. E, 2000, Pages

  Ferguson, James J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Enoxaparin; Glycoprotein IIb IIIa antagonist

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; TIROFIBAN; TYROSINE;

ACUTE DISEASE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; FEASIBILITY STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NORTH AMERICA; SAFETY;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEASIBILITY STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; NORTH AMERICA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SAFETY; TYROSINE;

EID: 0034571656     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-318.
2. Cohen M, Demers C, Gurfinkel EP, et al. for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
3. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997;27:1474-1482.
4. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
5. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial. Circulation 1998;97:1702-1707.
6. Antman EM, Cohen M, Radley DR, et al. for the TIMI-11B and ESSENCE Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI-11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
7. Grines C. Oral presentation. American College of Cardiology, 2000.
8. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
9. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:2429-2435.
10. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
11. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
12. The RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac event in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasry. Circulation 1997;96:1445-1453.
13. PRISM-PLUS study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
14. The IMPACT-II investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428.
15. The PURSUIT Trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
16. Hirsh J. Low-molecular-weight heparin: A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998;98:1574-1582.
17. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
18. Klein W, Buchwald A, Hillis SE, et al. for the FRIC investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for six weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997;96:61-68.
19. FRagmin and Fast Revascularization during Instability in Coronary artery disease (FRISC) investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicenter study. Lancet 1999;354:701-707.
20. FRagmin and Fast Revascularization during Instability in Coronary artery disease (FRISC) investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicenter study. Lancet 1999;354:708-715.
21. The FRAXIS Study Group. Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-1562.
22. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111.
23. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet 2000;355:1936-1942.
24. Kaul S, Shah PK. Low-molecular-weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000;35:169-712.
25. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
26. Kereiakes D, Fry E, Lengerich R, et al. Abciximab-associated thrombocytopenia is reduced by enoxaparin: Preliminary results of the NICE 4 trial. Am J Cardiol 1999;84:67P.
27. Cohen M. Oral presentation. ESC 1999.